Nyxoah

What we do: Nyxoah is a medical technology company dedicated to reinventing sleep for the billion people suffering from obstructive sleep apnea (OSA). We develop breakthrough treatment alternatives through neuromodulation, focusing on our flagship product, Genio®, a battery-free hypoglossal nerve stimulation device. This minimally invasive implant is inserted through a single incision under the chin and controlled by a wearable external activation chip, offering a patient-centric alternative to traditional CPAP therapy for moderate to severe OSA.

Where we are located: Our headquarters are located at rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium.

Short history: Founded in 2009, Nyxoah has grown into a pioneering company in the field of neurostimulation for sleep apnea. Key milestones include the development and CE marking of the Genio® system and ongoing clinical trials such as the DREAM study aimed at expanding regulatory approvals, including in the US market.

Organization & culture: Nyxoah employs approximately 184 people and fosters a culture of innovation, passion, and patient-centricity. Our teams are driven by a commitment to improving patient outcomes through cutting-edge technology and clinical evidence, emphasizing collaboration and continuous improvement.

Recent developments: Nyxoah continues to advance its clinical programs and expand its commercial footprint in Europe and Australia. The company is actively investing in research and development, with significant resources dedicated to pivotal clinical trials and regulatory submissions to broaden access to its innovative therapies.